000			03812nam a22004455i 4500
999			_c381865 _d381865 _x1
001			381865
003			ES-MaUEC
005			20230102121936.0
006			a||||fo|||| 00| 0
007			cr nn 008mamaa
008			220512s2022 sz | s |||| 0|eng d
020			_a9783030963767
024	7		_a10.1007/978-3-030-96376-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC271.I45 _b2022 EB
245	0	0	_aCancer Immunotherapies : _bSolid Tumors and Hematologic Malignancies _cedited by Priya Hays
250			_aFirst edition 2022
264		1	_aCham _bSpringer International Publishing _c2022
300			_a1 recurso en línea (XVI, 315 páginas) _b32 ilustraciones, 31 ilustraciones a color
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aCancer Treatment and Research _x2509-8497 ; _v183
505	0		_aDevelopment of Cancer Immunotherapies -- Melanoma -- Engaging pattern recognition receptors in solid tumors to generate systemic anti-tumor immunity -- Allogeneic tumor antigen-specific T cells for broadly applicable adoptive cell therapy of cancer -- Chimeric Antigen Receptor (CAR) T Cell Therapy for Glioblastoma -- Lag3: From Bench to Bedside -- Immunotherapy in Genitourinary Malignancy: evolution in revolution or revolution in evolution -- Immune-based therapeutic interventions for Acute Myeloid Leukemia.-Off-the-shelf chimeric antigen receptor immune cells from human pluripotent stem cells -- The single-cell level perspective of the tumor microenvironment and its remodeling by CAR-T cells -- Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematological Malignancies.
520			_aThis book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer immunotherapies fall broadly into three categories: immune checkpoint inhibitors (ICIs), adoptive T cell therapies, and cancer vaccines which have distinct mechanisms of action. Immune checkpoint inhibitors rely upon disrupting tumor antigen recognition as self by the immune system through inhibition of checkpoint molecules. Adoptive T cell therapies involve the engineering of T cells ex vivo to target and destroy tumor cells. The first part of this book will provide an overview of the discovery and mechanistic details of the technology. The second part will be devoted to elaborating on the clinical outcomes, successes and limitations for specific tumor subtypes, which includes both solid tumors and hematologic malignances for both pediatric and adult populations. As such, the book offers a valuable resource for oncologists, hematologists, and all those seeking an up-to-date overview of cancer immunotherapies.
988			_aSpringer_Medicine_2022
650		7	_2embne _9195595 _aCáncer _xAspectos inmunológicos
700	1		_aHays, Priya _eeditor literario _4 _4http://id.loc.gov/vocabulary/relators/edt _9682237
773	0		_tSpringer Nature eBook
776	0	8	_iPrinted edition: _z9783030963750
776	0	8	_iPrinted edition: _z9783030963774
776	0	8	_iPrinted edition: _z9783030963781
830		0	_aCancer Treatment and Research, _x2509-8497 ; _v183
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-96376-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b09/2022 _dz _eIG _zSI